BTMD vs NUVB vs KYMR vs HIMS vs ARVN

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). biote Corp. (BTMD) offers the better valuation at 2. 9x trailing P/E, making it the more compelling value choice. Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, biote Corp.

(BTMD) is the cheapest at 2. 9x versus Hims & Hers Health, Inc. at 55. 4x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -83. 5% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: HIMS returned +188. 5% versus BTMD's -78. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arvinas, Inc.

(ARVN) is the lower-risk stock at 0. 99β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 151% more volatile than ARVN relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: biote Corp. grew EPS 703. 5% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

biote Corp.

(BTMD) is the more profitable company, earning 14. 1% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 14. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTMD leads at 18. 5% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVB: 158.

9% to $12. 40.

In this comparison, BTMD (2.

2% yield) pays a dividend. NUVB, KYMR, HIMS, ARVN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +158. 8% 10Y return). Nuvation Bio Inc. (NUVB) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +158. 8%, NUVB: -52. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BTMD is a small-cap deep-value stock; NUVB is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; ARVN is a small-cap quality compounder stock. BTMD pays a dividend while NUVB, KYMR, HIMS, ARVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.